Multiply Intercalator-Substituted Cu(II) Cyclen Complexes as DNA Condensers and DNA/RNA Synthesis Inhibitors

Many drugs that are applied in anticancer therapy such as the anthracycline doxorubicin contain DNA-intercalating 9,10-anthraquinone (AQ) moieties. When Cu­(II) cyclen complexes were functionalized with up to three (2-anthraquinonyl)­methyl substituents, they efficiently inhibited DNA and RNA synthe...

Full description

Saved in:
Bibliographic Details
Published inInorganic chemistry Vol. 57; no. 9; pp. 5004 - 5012
Main Authors Hormann, Jan, Malina, Jaroslav, Lemke, Oliver, Hülsey, Max J, Wedepohl, Stefanie, Potthoff, Jan, Schmidt, Claudia, Ott, Ingo, Keller, Bettina G, Brabec, Viktor, Kulak, Nora
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 07.05.2018
Online AccessGet full text

Cover

Loading…
More Information
Summary:Many drugs that are applied in anticancer therapy such as the anthracycline doxorubicin contain DNA-intercalating 9,10-anthraquinone (AQ) moieties. When Cu­(II) cyclen complexes were functionalized with up to three (2-anthraquinonyl)­methyl substituents, they efficiently inhibited DNA and RNA synthesis resulting in high cytotoxicity (selective for cancer cells) accompanied by DNA condensation/aggregation phenomena. Molecular modeling suggests an unusual bisintercalation mode with only one base pair between the two AQ moieties and the metal complex as a linker. A regioisomer, in which the AQ moieties point in directions unfavorable for such an interaction, had a much weaker biological activity. The ligands alone and corresponding Zn­(II) complexes (used as redox inert control compounds) also exhibited lower activity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0020-1669
1520-510X
DOI:10.1021/acs.inorgchem.8b00027